JP6340320B2 - 変形性関節症の治療において使用されるヘルパー依存性アデノウイルスベクターを含む医薬組成物 - Google Patents
変形性関節症の治療において使用されるヘルパー依存性アデノウイルスベクターを含む医薬組成物 Download PDFInfo
- Publication number
- JP6340320B2 JP6340320B2 JP2014555328A JP2014555328A JP6340320B2 JP 6340320 B2 JP6340320 B2 JP 6340320B2 JP 2014555328 A JP2014555328 A JP 2014555328A JP 2014555328 A JP2014555328 A JP 2014555328A JP 6340320 B2 JP6340320 B2 JP 6340320B2
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- acid sequence
- pharmaceutical composition
- helper
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims description 81
- 201000008482 osteoarthritis Diseases 0.000 title claims description 80
- 230000001419 dependent effect Effects 0.000 title claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 106
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 97
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims description 94
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims description 93
- 230000014509 gene expression Effects 0.000 claims description 42
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 206010061218 Inflammation Diseases 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 241000283073 Equus caballus Species 0.000 claims description 16
- 241000701161 unidentified adenovirus Species 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 12
- 241001529936 Murinae Species 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102000000013 Chemokine CCL3 Human genes 0.000 claims description 6
- 108010057466 NF-kappa B Proteins 0.000 claims description 6
- 102000003945 NF-kappa B Human genes 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 230000003349 osteoarthritic effect Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 102000000589 Interleukin-1 Human genes 0.000 claims description 5
- 108010002352 Interleukin-1 Proteins 0.000 claims description 5
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 4
- 101710155856 C-C motif chemokine 3 Proteins 0.000 claims description 3
- 108700012434 CCL3 Proteins 0.000 claims description 3
- 101150101999 IL6 gene Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 229940100601 interleukin-6 Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 101001076415 Bos taurus Interleukin-1 receptor antagonist protein Proteins 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000001503 joint Anatomy 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 30
- 210000000845 cartilage Anatomy 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 17
- 210000002437 synoviocyte Anatomy 0.000 description 12
- 241000283086 Equidae Species 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 238000011161 development Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000030175 lameness Diseases 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000010603 microCT Methods 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000008355 cartilage degradation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008409 synovial inflammation Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101710150451 Protein Bel-1 Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000046824 human IL1RN Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000002967 posterior cruciate ligament Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
高レベルのIl−1Raが、本発明のヘルパー依存性アデノウイルスベクター(HDAd)により感染された滑膜細胞の上清中で計測された。以下に示されるとおり、リポ多糖(LPS)による炎症の誘導は、未誘導試料と比較してIl−1Ra濃度の大幅な増加に導いた。Il−1Raは、未感染試料(モック)中でも対照ベクター(HDAd−GFP)により感染された試料中でも検出されなかった。実験は、HDAd−mIl−1Raにより感染された細胞が高レベルのIl−1−RAを産生し得ることを実証する。これは、Il−1Raがそれらの細胞から有効に分泌されること、および炎症病態がNF−κB5−ELAMプロモーターを活性化させ、Il−1Raレベルの増加に導くことをさらに示す。
図1は、本発明のHDAdベクターの遺伝子地図を示す。完全ベクター配列を配列番号2または配列番号3に示す。この2つのベクター間の唯一の差異は、GQ−201がIl−1Raのウマバリアントを有する一方、HDAd−mIl−RaがネズミIl−1Raバリアントを有することである。両方のベクターは、配列番号1によるIl−1RaのcDNAの上流の炎症誘導性NF−κB5−ELAMプロモーターならびに逆方向末端反復(ITR)およびアデノウイルスパッケージングシグナルを含有する。ベクターを以下の方針に従って標準的な消化/ライゲーション反応によりクローニングした。NF−κB5−ELAMプロモーターにより駆動されるルシフェラーゼcDNAを含有するプラスミドであるpNifty−luc中のルシフェラーゼcDNAを、NcoIおよびNheIにより切り取り、ウマまたはネズミIl−1RaについてのcDNAをこの位置中にライゲートした。NF−κB5−ELAMプロモーター−ネズミIl−1RaまたはNF−κB5−ELAMプロモーター−ウマIl−1RaカセットをNotIおよびPacIまたはEcoRIおよびPacIにより切り取り、平滑末端化し、pLPBLシャトルプラスミド中に挿入し、それをSalIにより線形化および平滑末端化した。次いで、NF−κB5−ELAMプロモーター−ネズミIl−1RaまたはNF−κB5−ELAMプロモーター−ウマIl−1RaカセットをAscIにより切り取り、マルチプルクローニング部位の両側をフランキングし、AscIにより線形化されたpΔ28プラスミド(Toietta, G., Pastore, L., Cerullo, V., Finegold, M., Beadet, A. L., and Lee, B.(2002).Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5,204−210.)中にライゲートし、ゲノムプラスミドpΔ28−mIl−1RaおよびpΔ28−eqIl−1Raを得た。これらのプラスミドをPmeIにより消化してベクターを線形化し、逆方向末端反復を遊離させ、細菌耐性遺伝子を切り取った。ヘルパーウイルスAdNG163R−2および116の細胞工場を使用して以前に記載のとおりベクターをレスキューし、増幅させた(Palmer, D., and Ng, P.(2003).Improved system for helper-dependent adenoviral vector production. Mol Ther 8,846−852; Suzuki, M., Cela, R., Clarke, C., Bertin, T. K., Mourino, S., and Lee, B.(2010).Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories, Hum Gene Ther 21,120−126.)。
長期遺伝子発現を関節中で最大1年間測定するため、マウスに本発明のヘルパー依存性アデノウイルスベクター(HDAd)、および比較のため、ホタルルシフェラーゼ(luc)をCMVプロモーターの制御下で発現する第1世代アデノウイルス(Ad)ベクターを関節内注射した。生体内(in vivo)生物発光イメージングを使用してluc発現を経時的に追跡した。強力な初期lucシグナルが両方のベクターの注射3日後に検出された(図2A)。その後、発現は両方のベクターについて減少し、第1世代ベクターAd−lucについては1ヵ月後に検出不能であった(図2B)。しかしながら、HDAd−lucルシフェラーゼ発現は、10日目に安定し、380日間このレベルであった。
マウス関節中でのHDAdトランスダクションを詳細に評価するため、マウスにLacZ発現HDAdを関節内注射した。強力なLacZ発現が滑膜中で見られたが、発現をコンドロサイト中で観察することはできなかった(図3)。本発明者らは、これらの動物の肝臓も分析してウイルスが関節から逃避するか否か、または注射の間に流出するか否かを評価した。最も重要なことに、バックグラウンドを超える検出可能なベクター濃度を定量的PCRにより計測することができなかった(データ示さず)。したがって、ベクターは、関節中で特異的に局在し、関節に残留し、そのことは最小の副作用を示唆するため変形性関節症病態の治療または予防において大きな利益である。
炎症誘導性NF−κB5−ELAMプロモーターの制御下でIl−1Raを発現するHDAdを生成し、その機能性をインビトロで試験した。高レベルのIl−1RaがHDAd−Il−1Ra感染細胞の上清中で3日目に計測された(図4)。リポ多糖(LPS)による炎症の誘導は、未誘導試料と比較してIl−1Ra濃度の大幅な増加に導いた。Il−1Raは、未感染試料(モック)中でも対照ベクター(HDAd−GFP)により感染された試料中でも検出されなかった。
Il−1Raを発現するHDAdがOAの発症を予防し得るか否かを評価するため、マウスの膝関節にHDAd−Il−1RaまたはGFP発現対照ベクター(HDAd−GFP)を関節内注射した。注射2日後、十字靭帯切断を実施してOA発症を誘導した。この変形性関節症モデルは、Dr. Brendan Leeの研究グループにおいて開発され、いくつかの実験においてバリデートされた(Ruan, Z., Dawson, B., Jiang M. M., Gannon, F., Heggenes, M., Lee, B.(2012).Quantitative volumetric imaging of murine osteoarthritic cartilage by phase contrast micro-computed tomography, submitted)。このモデルは、重度のOAの発症に導く膝関節の前および後十字靭帯の切断を含む。マウスをOA誘導1ヵ月後に安楽死させ、関節を組織学的に調製し、サフラニンOにより染色した。OAの発症を盲検化された病理学者によりOARSI(Osteoarthritis Research Society International)規格(1〜6のスケールのスコアの割り当て、1:OAの徴候が全く見られない、6:最大のOA)に従ってスコアリングした。HDAd−Il−1Ra処理関節は、HDAd−GFP処理または未処理関節よりも有意に低いOAスコアを有し、そのことは、HDAd−Il−1RaがOAの発症を予防したことを示唆する(図5)。対照ベクターHDAd−GFPは、平均OAスコアが未処理群のスコアと同等であったため、OAの発症に対するいかなる効果も有さないと考えられた。
OAの治療におけるHDAd−mIl−1Raの効力を、上記のネズミ疾患モデルにおいて評価した。このモデルを使用してHDAd−Il1−RaがOAを有効に治療し得るか否かを評価した。したがって、OAを十字靭帯切断により誘導し(未切断群を除く)、OAを2週間発症させた。次いで、HDAd−Il−1Ra、対照ベクター(HDAd−GFP)またはビヒクルを注射し、さらに6週間後にマウスを安楽死させて関節を分析した。HDAd−GFP処理および未注射マウスはOAを同一程度発症し、平均スコアは約4.5であった(図6A)。しかしながら、HDAd−Il−1Ra処理マウスは、HDAd−GFPおよびモック処理と比較して有意に低いOAスコアを有した。HDAd−Il−1Raと未切断(OA不含)マウスとの間に有意差は見出されず、そのことは、疾患の有効な治療またはその予防を示唆する。本発明者らは、この実験において関節をマイクロコンピュータ断層撮影(μCT)分析によりさらに評価した。この技術は、高分解能(0.5ミクロンまで)x線CT走査を位相差光学試験と組み合わせ、小動物関節中の軟骨の可視化を可能とする。関節の3次元再構築およびコンピュータによる組織分析ツールを使用していくつかの軟骨パラメータ、例えば、体積および表面積を定量することができる。HDAd−Il−1Ra処理関節は、HDAd−GFPおよびモック処理関節と比較して有意に高い軟骨体積を実証した(図6B)。HDAd−Il−1Raと未切断(OA不含)群との間に有意差は見られなかった。さらに、軟骨表面積は、HDAd−Il−1Ra処理マウスにおいてHDAd−GFPおよびモック群と比較して有意に大きかった(図6C)一方、HDAd−Il−1Raと未切断(OA不含)関節との間に有意差は見られなかった。
Claims (8)
- ヒトまたは他の哺乳動物インターロイキン−1受容体アンタゴニスト(Il−1Ra)をコードする核酸配列、左右逆方向末端反復(LITRおよびRITR)、アデノウイルスパッケージングシグナルおよび非ウイルス非コードスタッファー核酸配列を含有し、変形性関節症対象の関節中に直接投与されるヘルパー依存性アデノウイルスベクターを含む、変形性関節症の治療または予防のための医薬組成物であって、前記ヒトまたは他の哺乳動物Il−1Ra遺伝子の発現は、ヒトまたは他の哺乳動物Il−1Raをコードする前記核酸配列のリーディングフレームの上流に局在し、かつ免疫刺激物質により活性化される一成分炎症誘導性プロモーターにより調節される、医薬組成物。
- 前記炎症誘導性プロモーターは、NF−κBプロモーター、インターロイキン6(Il−6)プロモーター、インターロイキン−1(Il−1)プロモーター、腫瘍壊死因子(TNF)プロモーター、シクロオキシゲナーゼ2(COX−2)プロモーター、補体因子3(C3)プロモーター、血清アミロイドA3(SAA3)プロモーター、またはマクロファージ炎症性タンパク質−1α(MIP−1α)プロモーターからなる群から選択される、請求項1に記載の医薬組成物。
- 前記ヘルパー依存性アデノウイルスベクターは、配列番号2もしくは配列番号3に記載の核酸配列、または生物学的に有効なその部分を含み、
前記有効な部分は、配列番号2または配列番号3を含むベクターと配列相同性を有し、Il−1Raを発現することによってIl−1の効果を中和するための活性を有する、請求項1または2に記載の医薬組成物。 - 前記哺乳動物Il−1Raは、ネズミIl−1Ra、ウマIl−1Ra、イヌIl−1Ra、ネコIl−1Ra、ウサギIl−1Ra、ハムスターIl−1Ra、ウシIl−1Ra、ラクダIl−1Raまたは他の哺乳動物種のそれらのホモログからなる群から選択される、請求項1に記載の医薬組成物。
- 前記ヘルパー依存性アデノウイルスベクターは、ベクターゲノムのモニタリングを可能とするマーカー遺伝子をさらに含む、請求項1〜4のいずれか一項に記載の医薬組成物。
- 前記ヘルパー依存性アデノウイルスベクターは、配列番号1に記載の核酸配列またはその核酸配列によってコードされるアミノ酸配列と同一のアミノ酸配列をコードする保存核酸配列を含む、請求項1〜5のいずれか一項に記載の医薬組成物。
- Il−1Raは、配列番号1に記載の核酸配列と少なくとも90%の配列相同性を有し、生物学的に活性なIl−1Raタンパク質をコードする核酸配列を含む、請求項1〜6のいずれか一項に記載の医薬組成物。
- 非ヒト哺乳動物関節における、変形性関節症または変形性関節症の状態の治療または予防のための、請求項1〜7のいずれか一項に記載の医薬組成物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20120000703 EP2623604B8 (en) | 2012-02-02 | 2012-02-02 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
EP12000703.4 | 2012-02-02 | ||
PCT/IB2013/000198 WO2013114199A1 (en) | 2012-02-02 | 2013-01-23 | Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018016342A Division JP2018075035A (ja) | 2012-02-02 | 2018-02-01 | 変形性関節症の治療において使用されるアデノウイルスベースの生物学的送達および発現系 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015506695A JP2015506695A (ja) | 2015-03-05 |
JP6340320B2 true JP6340320B2 (ja) | 2018-06-06 |
Family
ID=47891791
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014555328A Active JP6340320B2 (ja) | 2012-02-02 | 2013-01-23 | 変形性関節症の治療において使用されるヘルパー依存性アデノウイルスベクターを含む医薬組成物 |
JP2018016342A Pending JP2018075035A (ja) | 2012-02-02 | 2018-02-01 | 変形性関節症の治療において使用されるアデノウイルスベースの生物学的送達および発現系 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018016342A Pending JP2018075035A (ja) | 2012-02-02 | 2018-02-01 | 変形性関節症の治療において使用されるアデノウイルスベースの生物学的送達および発現系 |
Country Status (12)
Country | Link |
---|---|
US (4) | US10301647B2 (ja) |
EP (1) | EP2623604B8 (ja) |
JP (2) | JP6340320B2 (ja) |
CN (1) | CN104245941B (ja) |
AU (1) | AU2013213873B2 (ja) |
CA (1) | CA2861408C (ja) |
DK (1) | DK2623604T3 (ja) |
EA (1) | EA033004B1 (ja) |
ES (1) | ES2534782T3 (ja) |
IN (1) | IN2014KN01682A (ja) |
PL (1) | PL2623604T3 (ja) |
WO (1) | WO2013114199A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2948553B1 (en) * | 2013-01-25 | 2020-04-01 | Baylor College Of Medicine | A helper-dependent adenoviral gene therapy delivery and expression system |
GB201410314D0 (en) * | 2014-06-10 | 2014-07-23 | Advanced Risc Mach Ltd | Display controller |
CN107636146A (zh) * | 2015-03-02 | 2018-01-26 | 同生公司 | 被工程化为治疗受益于降低的消化道炎症和/或收紧的消化道粘膜屏障的疾病的细菌 |
WO2017123934A1 (en) | 2016-01-13 | 2017-07-20 | Merial, Inc. | Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals |
AU2017313844B2 (en) | 2016-08-19 | 2023-10-12 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
WO2018071295A1 (en) | 2016-10-10 | 2018-04-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inducible production of anti-inflammatory cytokines |
CN110225923A (zh) * | 2016-12-07 | 2019-09-10 | 佛罗里达大学研究基金会有限公司 | IL-1Ra cDNA |
JP7260173B2 (ja) | 2017-04-21 | 2023-04-18 | ベイラー カレッジ オブ メディスン | 腫瘍溶解性ウイルス療法および免疫療法 |
EP4031192A4 (en) * | 2019-09-18 | 2023-10-25 | Pacira Therapeutics, Inc. | EFFECTIVE DOSAGE OF AN ADENOVIRUS BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS IN HUMAN BEINGS AND COMPOSITIONS THEREOF |
JPWO2022234844A1 (ja) * | 2021-05-06 | 2022-11-10 | ||
KR20240052793A (ko) * | 2021-08-24 | 2024-04-23 | 파시라 테라퓨틱스, 인크. | 추간판 퇴행에 대한 IL-1Ra 유전자 요법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747072A (en) | 1993-07-30 | 1998-05-05 | University Of Michigan | Adenoviral-mediated gene transfer to synovial cells in vivo |
US20030091536A1 (en) | 1999-09-07 | 2003-05-15 | Colorado State University Research Foundation | In vivo treatment of joint disease using interleukin-1 |
FR2806418B1 (fr) * | 2000-03-14 | 2004-07-16 | Aventis Pharma Sa | Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations |
WO2002083080A2 (en) | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
ES2569917T3 (es) * | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
WO2010127275A1 (en) * | 2009-05-01 | 2010-11-04 | Oregon Health & Scince University | Method of expanding human hepatocytes in vivo |
CA2763161A1 (en) * | 2009-05-29 | 2010-12-02 | Xoma Technology Ltd. | Cardiovascular related uses of il-1.beta. antibodies and binding fragments thereof |
-
2012
- 2012-02-02 PL PL12000703T patent/PL2623604T3/pl unknown
- 2012-02-02 DK DK12000703.4T patent/DK2623604T3/da active
- 2012-02-02 ES ES12000703.4T patent/ES2534782T3/es active Active
- 2012-02-02 EP EP20120000703 patent/EP2623604B8/en active Active
-
2013
- 2013-01-23 US US14/375,351 patent/US10301647B2/en active Active
- 2013-01-23 IN IN1682KON2014 patent/IN2014KN01682A/en unknown
- 2013-01-23 WO PCT/IB2013/000198 patent/WO2013114199A1/en active Application Filing
- 2013-01-23 CA CA2861408A patent/CA2861408C/en active Active
- 2013-01-23 EA EA201491457A patent/EA033004B1/ru unknown
- 2013-01-23 JP JP2014555328A patent/JP6340320B2/ja active Active
- 2013-01-23 AU AU2013213873A patent/AU2013213873B2/en active Active
- 2013-01-23 CN CN201380007814.1A patent/CN104245941B/zh active Active
-
2018
- 2018-02-01 JP JP2018016342A patent/JP2018075035A/ja active Pending
-
2019
- 2019-04-30 US US16/398,691 patent/US20190376080A1/en not_active Abandoned
-
2021
- 2021-10-08 US US17/497,045 patent/US20220073948A1/en not_active Abandoned
-
2022
- 2022-06-30 US US17/855,322 patent/US20220348963A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2623604B1 (en) | 2015-02-25 |
US20150031083A1 (en) | 2015-01-29 |
US20190376080A1 (en) | 2019-12-12 |
US20220348963A1 (en) | 2022-11-03 |
AU2013213873B2 (en) | 2018-06-21 |
ES2534782T3 (es) | 2015-04-28 |
PL2623604T3 (pl) | 2015-07-31 |
CA2861408C (en) | 2021-10-26 |
US10301647B2 (en) | 2019-05-28 |
EA201491457A1 (ru) | 2014-11-28 |
EP2623604B8 (en) | 2015-04-22 |
DK2623604T3 (da) | 2015-06-01 |
CN104245941B (zh) | 2016-12-07 |
CA2861408A1 (en) | 2013-08-08 |
AU2013213873A1 (en) | 2014-09-25 |
EP2623604A1 (en) | 2013-08-07 |
JP2015506695A (ja) | 2015-03-05 |
US20220073948A1 (en) | 2022-03-10 |
WO2013114199A1 (en) | 2013-08-08 |
JP2018075035A (ja) | 2018-05-17 |
WO2013114199A8 (en) | 2014-09-25 |
EA033004B1 (ru) | 2019-08-30 |
CN104245941A (zh) | 2014-12-24 |
IN2014KN01682A (ja) | 2015-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6340320B2 (ja) | 変形性関節症の治療において使用されるヘルパー依存性アデノウイルスベクターを含む医薬組成物 | |
US20200407746A1 (en) | Muscle-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | |
KR102502974B1 (ko) | 향상된 입양 세포 치료 | |
US20220282280A1 (en) | Helper-dependent adenoviral gene therapy delivery and expression system | |
Watson Levings et al. | Gene therapy for osteoarthritis: pharmacokinetics of intra-articular self-complementary adeno-associated virus interleukin-1 receptor antagonist delivery in an equine model | |
Nalbantoglu et al. | Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle | |
JP7066861B2 (ja) | Pah遺伝子移入のためのアデノ随伴ウイルス組成物及びそれらの使用方法 | |
Minter et al. | Adenoviral delivery of human and viral IL-10 in murine sepsis | |
US11813337B2 (en) | Tumor-targeting synthetic adenoviruses and uses thereof | |
Hofherr et al. | Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy | |
CN111630159A (zh) | 重组腺病毒及包含此病毒的干细胞 | |
Mian et al. | Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors | |
Grol | The evolving landscape of gene therapy strategies for the treatment of osteoarthritis | |
JP6153205B2 (ja) | Va遺伝子破壊アデノウイルスベクターおよびそれを調製するための前駆体ベクター | |
Yeung et al. | Tissue Targeted and Regulated Gene Expression | |
Frisbie | Interleukin-1 receptor antagonist delivery through adenoviral mediated gene transfer as a treatment for equine joint disease | |
WO2004016652A2 (en) | Mammaglobin promoter | |
Arendt | Development of telomerase targeted gene therapy for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20171003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180201 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180326 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180424 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180514 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6340320 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |